SCHEMBL6498155

SCHEMBL6498155

CCC(C)(C)CC[C@H](Nc1nc(=O)oc2ccccc12)C(=O)O

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.46
KMT2A Q03164 6/20 0.44
MEN1 O00255 4/20 0.44
HSD17B10 Q99714 2/20 0.39
MAPT P10636 2/20 0.39
MAPK1 P28482 1/20 0.39
USP2 O75604 1/20 0.39
LMNA P02545 1/20 0.39
PKM P14618 1/20 0.38
HPGD P15428 1/20 0.38
HTT P42858 1/20 0.38
CYP2C9 P11712 1/20 0.38
GAA P10253 1/20 0.37
KCNA5 P22460 1/20 0.36
NQO1 P15559 1/20 0.36
KDM4E B2RXH2 1/20 0.35
ELANE P08246 1/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4834842 1.00 ALDH1A1 (0.46) ALDH1A1KMT2AMEN1HSD17B10MAPT
SCHEMBL4828758 0.90 ALDH1A1 (0.46) ALDH1A1KMT2AMEN1HSD17B10MAPT
SCHEMBL4828733 0.86 ALDH1A1 (0.34) ALDH1A1KMT2AMEN1NQO1KDM4E
SCHEMBL5365086 0.83 ALDH1A1 (0.47) ALDH1A1KMT2AMEN1HSD17B10MAPT
SCHEMBL6496216 0.83 ALDH1A1 (0.47) ALDH1A1KMT2AMEN1HSD17B10MAPT
SCHEMBL6495982 0.81 ALDH1A1 (0.46) ALDH1A1KMT2AMEN1HSD17B10MAPT
SCHEMBL6495976 0.81 ALDH1A1 (0.46) ALDH1A1KMT2AMEN1HSD17B10MAPT
SCHEMBL5363855 0.81 ALDH1A1 (0.63) ALDH1A1KMT2AMEN1HSD17B10MAPT
SCHEMBL6494571 0.81 ALDH1A1 (0.63) ALDH1A1KMT2AMEN1HSD17B10MAPT
SCHEMBL6504642 0.78 ALDH1A1 (0.41) ALDH1A1KMT2AMEN1MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6936606-B2 Cyanoamido-containing heterocyclic compounds useful as reversible inhibitors of cysteine proteases BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2005-08-30 US claimed
EP-1434769-A2 COMPOUNDS USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) 2004-07-07 EP claimed
US-20040063679-A1 Compounds useful as reversible inhibitors of cysteine proteases BOEHRINGER INGELHEIM PHARMACEUTICALS INC. 2004-04-01 US claimed
WO-2003029200-A2 COMPOUNDS USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2003-04-10 WO claimed
US-6936606-B2 Cyanoamido-containing heterocyclic compounds useful as reversible inhibitors of cysteine proteases BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2005-08-30 US disclosed
EP-1434769-A2 COMPOUNDS USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) 2004-07-07 EP disclosed
US-20040063679-A1 Compounds useful as reversible inhibitors of cysteine proteases BOEHRINGER INGELHEIM PHARMACEUTICALS INC. 2004-04-01 US disclosed
WO-2003029200-A2 COMPOUNDS USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2003-04-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063679-A1 Compounds useful as reversible inhibitors of cysteine proteases CTSS, CTSK, CTSB ALDH1A1 2191/4885KMT2A 4544/4885MEN1 3211/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.